Table 4.
Liver function tests.
| Numbers of participants (%) |
||
|---|---|---|
| At any time during treatment | At any time off-treatment | |
| Number who have had LFT testinga | 40 | 55 |
| Number with test result outside local normal range in any testa, b | 12 (30%) | 12 (22%) |
| Number with clinically significant results in any testa, b | 2 (5%) | 5 (9%) |
| Number with transaminase levels>3 times upper limit of normal in any testa, c | 2 (5%) | 3 (5%) |
| Number with both clinically significant and greater than 3 times of upper limit of normal in any testa | 1 (3%) | 3 (5%) |
a
Numbers provided are per participant (not including multiple participants).
b
Aspartate transaminase, alanine transaminase, alkaline phosphatase as a minimum and bilirubin and gamma-glutamyltransferase in some hospitals.
c
Transaminase levels>3 times upper limit of normal was the threshold to stop treatment with UPA as advised by the MHRA.